Soligenix Inc. (NASDAQ:SNGX) and Forty Seven Inc. (NASDAQ:FTSV) compete against each other in the Biotechnology sector. We will compare them and contrast their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix Inc.	5.52M	2.98	7.93M	-0.83	0.00
Forty Seven Inc.	N/A	0.00	65.49M	-2.06	0.00

Table 1 demonstrates Soligenix Inc. and Forty Seven Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

	Net Margins	Return on Equity	Return on Assets
Soligenix Inc.	-143.66%	-142.4%	-87%
Forty Seven Inc.	0.00%	0%	0%

Liquidity

The Current Ratio and Quick Ratio of Soligenix Inc. are 3.3 and 3.3 respectively. Its competitor Forty Seven Inc.’s Current Ratio is 11.9 and its Quick Ratio is 11.9. Forty Seven Inc. can pay off short and long-term obligations better than Soligenix Inc.

Institutional & Insider Ownership

Institutional investors held 23.1% of Soligenix Inc. shares and 67.3% of Forty Seven Inc. shares. About 14.4% of Soligenix Inc.’s share are held by insiders. Competitively, Forty Seven Inc. has 5.1% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Soligenix Inc.	2.2%	3.34%	-17.7%	-40%	-54.41%	8.14%
Forty Seven Inc.	1.35%	17.43%	-6.15%	12.09%	0%	9.73%

For the past year Soligenix Inc. was less bullish than Forty Seven Inc.

Summary

Forty Seven Inc. beats Soligenix Inc. on 5 of the 9 factors.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric CrohnÂ’s disease and acute radiation enteritis. This segment also offers SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase IB clinical trial for the treatment of vaccine against ricin toxin poisoning; VeloThrax, an anthrax vaccine candidate; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of melioidosis. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.